Release Date: 2024-05-28

Predicting Disease Recurrence and Progression

Release Date: 2024-05-28

In this section, NMIBC constitutes the majority of bladder cancer cases, characterized by a favorable prognosis. Recurrence and progression rates vary widely, highlighting the chronic nature of NMIBC and the need for extensive follow-up and treatment sessions. Various prognostic factors influence recurrence and progression, including tumor characteristics and patient demographics. Risk stratification tools like the [...]

Media Type
  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Management of Non-Muscle Invasive Bladder Cancer
First Page109
Last Page120
DOIhttps://doi.org/10.69860/nobel.9786053359197.9
ISBN978-605-335-919-7 (PDF)
LanguageENG
Page Count12
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing
In this section, NMIBC constitutes the majority of bladder cancer cases, characterized by a favorable prognosis. Recurrence and progression rates vary widely, highlighting the chronic nature of NMIBC and the need for extensive follow-up and treatment sessions. Various prognostic factors influence recurrence and progression, including tumor characteristics and patient demographics. Risk stratification tools like the EORTC and CUETO calculators aid in predicting probabilities at different time points, although current models have limitations. Factors like smoking and genetic alterations contribute to recurrence and progression risk. However, there’s a call for more efficient risk stratification tools incorporating new biomarkers and treatment strategies to enhance patient management.

Selamettin Demir (Author)
MD, Associate Professor of Urology, Van Regional Training and Research Hospital
https://orcid.org/0000-0003-1302-4127
3Selamettin Demir has been practising urology for more than fifteen years. In addition to various academic studies, I have publications on urooncology. At the same time, I have a 4-month fellowship service in the field of urooncology at Istanbul Medeniyet University. Currently, I am continuing my academic studies at the University of Health Sciences Van Training and Research Hospital.

Mustafa Kaan Akalin (Author)
MD, Ozalp State Hospital
https://orcid.org/0000-0003-1484-2906
3Dr. Mustafa Kaan Akalin has been a dedicated professional in the field of urology for over six years. He completed his undergraduate education at the Adnan Menderes Faculty of Medicine and subsequently Later, he became a urologist specialist with a residency at Istanbul Medeniyet University. Dr. Akalin has a distinguished record of scholarly contributions, having authored over 10 research articles and presented numerous oral and poster presentations. His current research focuses on the urooncology and endourology.He is an active member of both the Turkish Society of Urology and the European Assosiation Urology.

  • 6. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer; Lyon, France: 2018. [(accessed on 28 May 2024)]. Available online: https://gco.iarc.fr/

  • 21. Pasin E, Josephson DY, Mitra AP, Cote RJ, Stein JP. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 2008 Winter;10(1):31-43.

Share This Chapter!